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ABSTRACT Contact eczema (CE) is one of the most common skin dis-
eases and is regarded as a reaction pattern. However, the skin can 
react in the same way to different stimuli, some of which may act to-
gether. The golden standard in the diagnosis of allergic contact der-
matitis (ACD) is the patch test. Contact allergy to topical corticoste-
roids is known to be gradually rising, and this represents a significant 
problem in the treatment of contact eczema.
The aim of this study was to evaluate the prevalence of contact al-
lergy to European Baseline Series and Corticosteroid Series haptens 
in a population of patients with CE.
A group of 126 patients with the clinical diagnosis of contact eczema 
were patch tested with 28 European Baseline Series allergens and 8 
corticosteroid allergens in different concentrations and in different 
media: 80 (64.5%) women and 46 (36.5%) men, mean age 50.4 years. 
The average duration of CE was 6.9 years.
In total, 65 patients (51.6%) demonstrated an allergic reaction to at 
least one European Baseline Series allergen, and 22 patients (17.4%) 
to at least one corticosteroid. The most common allergens giving 
positive results were nickel sulfate (26.2%), cobalt chloride (15.1%), 
budesonide (14.3%), potassium dichromate (13.5%), and myroxylon 
pereirae resin (MPR) (11.9%). According our data, the European Base-
line Series tests allow the cause of ACD to be identified in over 50% 
of cases.
KEY WORDS: contact hypersensitivity, European baseline series hap-
tens, contact eczema
INTRODUCTION
Allergic contact dermatitis (ACD) is the conse-
quence of exposure to a hapten in a contact-sensi-
tized individual. Gell and Coombs classify ACD as a 
classic example of cell-mediated immune response 
resulting from type IV hypersensitivity. ACD requires 
the activation of antigen-specific acquired immunity, 
leading to the development of effector T cells which 
mediate skin inflammation (1). Contact dermatitis is 
one of the most common skin diseases, and has a con-
siderable socio-economic impact. However, although 
AKNOWLEDGEMENT
This study was supported by a grant for sci-
entific purposes No.502-03/1-152-01/502-
14-254 from the Medical University of Lodz, 
Poland. The authors report no conflict of 
interest.
ACTA DERMATOVENEROLOGICA CROATICA
30 ACTA DERMATOVENEROLOGICA CROATICA
Kot et al. Acta Dermatovenerol Croat
Contact hypersensitivity in patients with contact eczema    2016;24(1):29-36
the exact prevalence of contact allergy is unknown, 
allergic contact dermatitis may affect up to 55% of 
the adult population (2). There are also differences in 
the frequency of contact allergy to specific substances 
among citizens of different countries (3).
Contact allergy to corticosteroids is becoming 
increasingly recognized worldwide as a problem of 
considerable clinical and therapeutic importance, 
and was first observed soon after their introduction in 
the early 1950s. Burckhardt reported the first case of 
allergic contact dermatitis to hydrocortisone in 1959, 
and in that same year, Kooij reported ACD to both 
hydrocortisone and neomycin (4,5). ACD to steroids 
should be suspected if dermatitis worsens or does 
not improve following their use (6). The incidence 
of corticosteroid allergy is known to vary from 0.5% 
to 10.7%, depending on the center (7,8). This paper 
presents our clinical experience with patch testing 
using the European Baseline Series and corticoste-
roid haptens in a specific population of patients with 
contact eczema. 
PATIENTS AND METHODS
One hundred and twenty-six patients with contact 
eczema under the care of the Department of Derma-
tology and Venereology, Medical University of Lodz 
were examined. The diagnosis of contact dermatitis 
was established on the basis of clinical signs, medi-
cal history, and histopathological examination where 
necessary. Eighty patients were women and 46 were 
men (age range: 19-82 years, mean age 50.4). Before 
applying the patch tests, a detailed interview was 
performed concerning the previous course of the dis-
ease and the treatment. The disease duration ranged 
from 2 months to 42 years, with a mean duration of 
6.9 years. 
The interview focused on the use of applicable 
topical corticosteroids. The duration of topical steroid 
use (on and off) ranged from 0 to 20 years (mean 4.2 
years). In total, 74 (58.7%) patients were using local 
therapy ointments containing corticosteroids from 
group A, 30 (23.8%) from group B, 12 (9.5%) from 
group C, 89 (70.6%) from group D1, and 40 (31.7%) 
from group D. Many patients used ointments contain-
ing different groups of corticosteroids. Five patients 
had never used topical corticosteroids; they were 
treated with moisturizing ointments and pimecrolim-
us. No patients were taking systemic corticosteroids, 
immunosuppressive drugs, or antihistamines during 
the examination. 
Patch testing was only performed on patients in 
whom any treatment with antihistamines had been 
stopped in the previous week or immunosuppressive 
drug treatment in the previous two weeks. Although 
skin lesions were sometimes present during patch 
testing, their severity and location did not prevent 
the tests from being performed. In total, 111 (88.1%) 
patients experienced skin lesions on the hands, 25 
(29.8%) on the feet, 52 (41.3%) on the lower legs, 34 
(27.0%) on the trunk, and 40 (31.7%) on the face. Only 
moisturizing ointments were permitted during patch 
testing. Patients were patch tested with 28 European 
Baseline Series allergens and 8 corticosteroid aller-
gens at a range of concentrations and in various me-
dia (Table 1, Table 3). Chemotechnique Diagnostics 
allergens were used in this study.
We used 8 corticosteroid allergens in petrolatum 
base: budesonide (0.1% and 0.01%), betamethasone-
17-valerate (0.1%), triamcinolone acetonide (1%), 
alclomethasone-17,21-diproponate (1%), clobetasol-
17-propionate (1%), dexamethasone-21-phosphate 
disodium salt (1%), tixocortol-21-pivalate (0.1%), and 
hydrocortisone-17-butyrate (1% in alcohol and in 
petrolatum). Patch tests were read in all patients after 
2, 3, 4, 5, and 7 days since applications. 
RESULTS
Allergic reactions to at least one European Baseline 
Series allergen were observed in 65 patients (51.6%). 
The most common allergens giving positive results 
were nickel sulfate (26.2%), cobalt chloride (15.1%), 
potassium dichromate (13.5%), 0.01% budesonide 
(12.7%), 0.1% budesonide (11.9%), and myroxylon 
pereirae resin (MPR) (11.9%) (Table 1).
The most common forms of hypersensitivity ob-
served among female patients were to nickel sulfate 
(35%), cobalt chloride (20%), potassium dichromate 
(13.7%), 0.01% budesonide (13.7%), and MPR (8.7%). 
In male patients, the hypersensitivites most com-
monly observed were to MPR (17.4%), potassium 
dichromate (13%), 0.01% nickel sulfate (10.9%), and 
budesonide (10.9%). 
In 33 patients under the age of 40, nickel sulfate 
(33.3%), cobalt chloride (18.2%), potassium dichro-
mate and MPR (12.1% each) were the most common 
contact allergen. In 93 patients over the age of 40, al-
lergy to nickel sulfate was observed in 23.7% of pa-
tients, while allergies to cobalt chloride, potassium 
dichromate, and 0.01% budesonide were each ob-
served in 14%. 
In patients with a duration of contact eczema of 
less than 5 years (73 patients), the most common sen-
sitizing allergens were nickel sulfate (23.3%), cobalt 
chloride (17.8%), potassium dichromate (12.3%), and 
0.01% budesonide (11,0%). In those suffering over 
5 years (53 patients), the most common were nickel 
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sulfate (30.2%), potassium dichromate and 0.01% 
budesonide (15.1% each), and cobalt chloride and 
methylodibromoglutaronitrile (11.3% each). 
In our study, 22 patients out of 126 (17.4%) had 
an allergic reaction to at least one corticosteroid. The 
corticosteroid haptens giving most common posi-
tive results were 0.01% budesonide (12.7%), 0.1% 
budesonide (11.9%), and betamethasone and clo-
betasol (9.5% each) (Table 3). In female patients, the 
most commonly-observed reactions were to 0.01% 
budesonide (13.7%), 0.1% budesonide (9.0%), and be-
tamethasone (7.0%), while in men 0.1% budesonide 
and clobetasol (13.0% each) and 0.01% budesonide 
and betamethasone (10.9% each) were the most 
common. 
Hypersensitivity to a single corticosteroid was ob-
served in 8 patients, to two corticosteroids in 2 pa-
tients, to three in 2 patients, to four in 2 patients, to 
six in 4 patients, to seven in 3 patients, and to eight 
in 1 patient. Sixteen (72.7%) patients with hypersen-
sitivity to corticosteroids were also sensitized to non-
steroidal haptens included in the European Baseline 
Series. The corticosteroids included in European 
Baseline Series (budesonide 0.01% and tixocortol-21-
pivalate) revealed 19 (86.4%) cases of steroid allergy. 
Budesonide allergy was observed in 18 patients: 13 
cases demonstrated a positive result for budesonide 
at both concentrations (0.1% and 0.01%), 3 cases at 
0.01% and 2 cases at 0.1%. Allergy to hydrocortisone 
was observed in 12 patients: 7 cases with a positive 
result with hydrocortisone in petrolatum and alcohol, 













Duration of CE (years)
<5 (n=73) >15 (n=53)
No. % No. % No. % No. % No. % No. % No. %
Potassium dichromate 0.5% 11 13.7 6 13.0 17 13.5 4 12.1 13 14.0 9 12.3 8 15.1
Phenylenediamine 1% 3 3.7 2 4.3 5 3.9 3 9.1 2 2.1 1 1.4 4 7.5
Thiuram mix 1% 1 1.2 1 2.2 2 1.6 0 0.0 2 2.1 1 1.4 1 1.9
Neomycin sulfate 20% 2 2.5 0 0.0 2 1.6 0 0.0 2 2.1 1 1.4 1 1.9
Cobalt chloride 1% 16 20.0 3 6.5 19 15.1 6 18.2 13 14.0 13 17.8 6 11.3
Benzocaine 5% 1 1.2 2 4.3 3 2.4 0 0.0 3 3.2 1 1.4 2 3.8
Nickel sulfate 5% 28 35.0 5 10.9 33 26.2 11 33.3 22 23.7 17 23.3 16 30.2
Clioquinol 5% 2 2.5 0 0.0 2 1.6 1 3.0 1 1.1 0 0.0 2 3.8
Colophonium 20% 1 1.2 2 4.3 3 2.4 1 3.0 2 2.1 1 1.4 2 3.8
Paraben mix 16% 3 3.7 1 2.2 4 3.2 0 0.0 4 4.3 1 1.4 3 5.7
P-Phenylenediamine 0.1% 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Lanolin alcohol 30% 1 1.2 0 0.0 1 0.8 0 0.0 1 1.1 0 0.0 1 1.9
Mercapto mix 2% 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Epoxy resin 1% 0 0.0 1 2.2 1 0.8 0 0.0 1 1.1 1 1.4 0 0.0
Myroxylon pereirae resin 25% 7 8.7 8 17.4 15 11.9 4 12.1 11 11.8 6 8.2 9 17.0
Para tertiary butylphenol 
formaldehyde resin 1%
1 1.2 1 2.2 2 1.6 0 0.0 2 2.1 1 1.4 1 1.9
2-Mercaptobenzothiazole 2% 0 0.0 1 2.2 1 0.8 0 0.0 1 1.1 0 0.0 1 1.9
Formaldehyde 1% 2 2.5 0 0.0 2 1.6 1 3.0 1 1.1 1 1.4 1 1.9
Fragrance mix I 8% 4 5.0 3 6.5 7 5.5 3 9.1 4 4.3 2 2.7 5 9.4
Sesquiterpene lactone mix 0.1% 0 0.0 3 6.5 3 2.4 0 0.0 3 3.2 1 1.4 2 3.8
Quaternium-15 1% 3 3.7 0 0.0 3 2.4 1 3.0 2 2.1 2 2.7 1 1.9
2-Methoxy-6-n-pentyl-4-
benzoquinone 0.01%
0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Methylisothiazolinon 0.01% 0 0.0 1 2.2 1 0.8 0 0.0 1 1.1 1 1.4 0 0.0
Budesonide 0.01% 11 13.7 5 10.9 16 12.7 3 9.1 13 14.0 8 11.0 8 15.1
Tixocortol-21-pivalate 0.1% 3 3.7 3 6.5 6 4.8 2 6.1 4 4.3 3 4.1 3 5.7
Methylodibromoglutaronitrile 0.5% 4 5.0 3 6.5 7 5.5 1 3.0 6 6.4 1 1.4 6 11.3
Fragrance mix II 14% 2 2.5 1 2.2 3 2.4 1 3.0 2 2.1 0 0.0 3 5.7
Lyral 5% 1 1.2 0 0.0 1 0.8 0 0.0 1 1.1 0 0.0 1 1.9
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1 A, D1 Myroxylon pereirae resin, tixocortol
F 34 5 Hands 3 D1 Nickel, budesonide 0.01%
F 82 40 Lower legs 15 A, D1
Benzocaine, nickel, clioquinol, paraben mix, budesonide 




5 A, D1, D2
Nickel, budesonide (0.01%), tixocortol, hydrocortisone (1% 
alc.)
F 48 6 Hands, face 5 B, D1 Myroxylon pereirae resin, budesonide (0.01% and 0.1%)
F 37 1 Hands, face 1 A, D1
Cobalt, nickel, colophonium, myroxylon pereirae resin, 
budesonide (0.01% and 0.1%)
F 72 1 Hands, face 1 A, C, D1
Budesonide (0.01%), dexamethasone, hydrocortysone (1% 
alc.)
F 48 3 Hands, trunk 2 A, B, D1, D2
Chrome, nickel, myroxylon pereirae resin, budesonide (0.01% 





6 A, D1, D2
Cobalt, nickel, lanolin, budesonide (0.01% and 0.1%), 
methylodibromoglutaronitrile, betamethasone, 
triamcinolone, clobetasol, dexamethasone, hydrocortisone 




0.5 A, B, D1, D2
Budesonide (0.01% and 0.1%), alclomethasone, 





0.3 D1 Cobalt, nickel, betamethasone
F 54 5 Hands 1 A, D1
Nickiel, budesonide (0.1%), betamethasone, triamcinolone, 





Budesonide (0.01% and 0.1%), betamethasone, triamcinolone, 




20 A, B, C, D1, D2
Chrome, neomycin, cobalt, nickel, 
methylodibromoglutaronitrile, budesonide (0.01% and 0.1%), 
betamethasone, triamcinolone, clobetasol, dexamethasone, 




20 A, B, D1
Myroxylon pereirae resin, colophonium, benzothiazole, 
fragrance mix I, budesonide (0.01% and 0.1%), tixocortol, 
alclomethasone, betamethasone, triamcinolone, clobetasol, 
dexamethasone, hydrocortisone (1% alc. and petr.)
M 82 15 Lower limbs 10 A, B, D1





3 A, C, D1, D2
Chrome, cobalt, benzocaine, nickel, budesonide (0.01% and 
0.1%), betamethasone, clobetasol.
M 55 3 Hands 1.5 A, D1
Budesonide (0.01% and 0.1%), betamethasone, triamcinolone, 




6 A, D1, D2
Benzocaine, colphonium, paraben mix, myroxylon pereirae 
resin, tixocortol, budesonide (0.1%), betamethasone, 
clobetasole
M 62 7 Hands 6 A, D1 Clobetasole, hydrocortisone (1% alc.)
M 29 2 Hands 1 A, D1
Budesonide (0.01% and 0.1%), tixocortol, betamethasone, 
triamcinolone, clobetasol, dexamethasone, hydrocortisone 
(1% alc. and petr.)
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3 cases with only hydrocortisone in petrolatum, and 
2 cases with hydrocortisone in alcohol. 
Various sensitivities were found according to ste-
roid group. Sensitivity to group B occurred in 14.3%, 
to group D1 in 11.1%, to group D2 in 10.3%, to group 
C in 7.9%, and to group A in 4% (Table 4). In the group 
of patients with hypersensitivity to steroids, the most 
frequently obtained cross-reactions were those be-
tween groups B and D (59.1%), B and D1 (50.0%), B 
and D2 (50.0%), and D1 and D2 (45.4%). The preva-
lence of allergy to the group of steroids according to 
topical steroid used is shown in Table 5.
DISCUSSION
In almost all developed countries, nickel is cur-
rently the most common contact allergen. While this 
phenomenon was only noticed in the late 90s in Po-
land, it has been known for many years in Western 
Europe (9). Contact allergy to nickel affects 17% of 
adults (10). Nickel allergy is more common among 
women than men, affecting an estimated 20% of the 
female and 6% of the male populations of Western Eu-
rope (11), and significantly higher among individuals 
with a positive history of pierced ears and jewelry 
rash (12,13). In 2002, Jensen et al. found nickel allergy 
to be present in 3.9% of 305 Danish schoolgirls aged 
10-14 years and in 17.1% of 275 high-school girls 
aged 17-22 years, in whom the respective frequen-
cies of ear piercing were 68.9% and 86.2% (13). This 
can be explained by the introduction of the Danish 
Nickel Regulation that reduced the allowable con-
centration of nickel in products authorized for sale 
(12). In 1994, the European Union introduced the 
Nickel Directive (13), which limited the nickel re-
lease threshold from alloys and nickel-plated objects 
which have prolonged contact with the skin. These 
migration limits are 0.2 µg/cm2 per week for metal 
parts which are inserted into pierced ears and other 
pierced parts of the human body, and 0.5 µg/cm2 
per week for other products which have direct and 
prolonged contact with the skin (13). In the present 
study, 26.2% patients with CD, 35% of women and 
10.9% of men, were found to be sensitized to nickel. 
The frequency of contact allergy to nickel is higher in 
younger people. Piaserico et al. found the frequency 
of nickel allergy to be 6.9% among the elderly and 
24.2% among adults (14), while our present findings 
indicate the prevalence to be 33.3% among patients 
below 40 years of age and 23.7% for those aged over 
40 years.
Our findings also indicate that cobalt allergy oc-
curred in 15.1% cases: 20% of women and 6.5% of 
men. Cobalt allergy may affect up to 29.8% of pa-
tients with eczema (16). In 2008, Balato et al. demon-
strated a cobalt prevalence of 7.7% in older patients 
(15). Isolated allergy to this metal is rare. Sensitization 
to cobalt usually coexists with allergy to chromium in 
men and to nickel in women (17). In the present study, 
93.7% of women who demonstrated hypersensitivity 
to cobalt also were sensitized to nickel, while 100% 











Duration of CE (years)
<5 (n=73) >5 (n=53)
No. % No. % No. % No. % No. % No. % No. %
Budesonide 0.1% B 9 11.2 6 13.0 15 11.9 2 6.1 13 14.0 7 9.6 8 15.1
Betamethasone-17-
valerate 0.1%
D1 7 8.7 5 10.9 12 9.5 2 6.1 10 10.7 7 9.6 5 9.4
Triamcinolone 
acetonide 1%
B 5 6.2 3 6.5 8 6.3 1 3.0 7 7.5 4 5.5 4 7.5
Alclomethasone-17,21-
dipropionate 1%
D1 1 1.2 1 2.2 2 1.6 0 0.0 2 2.1 1 1.4 1 1.9
Clobetasol-17-
propionate 1%




C 6 7.5 3 6.5 9 7.1 1 3.0 8 8.6 5 6.8 4 7.5
Hydrocortisone-17-
butyrate 1% alk
D2 6 7.5 4 8.7 10 7.9 1 3.0 9 9.7 4 5.5 6 11.3
Hydrocortisone 1% D2 6 7.5 3 6.5 9 7.1 1 3.0 8 8.6 5 6.8 4 7.5
Budesonide 0,01% B 11 13.7 5 10.9 16 12.7 3 9.1 13 14.0 3 9.1 13 14.0
Tixocortol-21-pivalate 
0.1%
A 3 3.7 3 6.5 6 4.8 2 6.1 4 4.3 2 6.1 4 4.3
*CE: contact eczema
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of the men allergic to cobalt were also sensitized to 
chrome.
Chrome is a common occupational allergen. Con-
tact allergy to chrome is more frequent in men and 
older people (9). Common occupational sources are 
cement, chrome-tanned leather, bleaching agents, 
paints, and printing solutions. In patients with eczema, 
the frequency of hypersensitivity to chrome ranges 
from 5.0% to 20.6% (16,18). Our results showed that 
allergy to chrome occurred in 13.5% cases (13.7% of 
female and 13% of male patients). Its prevalence was 
12.1% in patients aged below 40 years of age and 
14% in those aged over 40 years.
Myroxylon pereirae resin is a natural substance 
used in the local treatment of burns, ulcers, and 
wounds. Its extracts and distillates are very often 
used as fragrant additives to cosmetics and can be an 
allergy marker to perfumes. In a study conducted by 
Avalos-Peralta et al. the prevalence of allergy to MPR 
was 5.79%, and was slightly higher in men (7.32%) 
than in women (4.91%) (19). In the present study, al-
lergy to MPR occurred in 11.9% cases (8.7% women 
and 17.4% men). Allergy to MPR is much more com-
mon in older people, especially in those with eczema 
of the lower limbs or with leg ulcers. Machet et al. 
found the occurrence of MPR allergy among patients 
with leg ulcers to be 40% (20).
As allergy to topical steroids is much more com-
mon than previously thought, contact allergy to 
corticosteroids represents a significant therapeutic 
problem in the treatment of such chronic derma-
toses as contact dermatitis. Clinical studies indicate 
that hypersensitivity to corticosteroids is becoming 
ever more common. Boffa et al. note that 5.98% of 
studied patients with contact eczema were allergic 
to one or more corticosteroids. The most common 
sensitivity was to tixocortol pivalate (4.5%), while 
91.3% of corticosteroid-allergic subjects were found 
to be allergic to a combination of tixocortol pivalate 
and budesonide (21). A Mayo Clinic study reports that 
10.69% of studied patients had an allergic reaction to 
at least one corticosteroid, with the most common 
sensitivities being to tixocortol pivalate (5.03%) and 
0.1% budesonide (3.07%) (8). Such a high percentage 
of patients with allergy to corticosteroids in our study 
may be explained by the fact that all of these patients 
were adults (mean age 50.4) with a long duration of 
contact eczema (mean 6.9 years) and several years of 
experience applying topical corticosteroids (mean 
4.2 years). Contact hypersensitivity to steroids was 
diagnosed in 12.3% of subjects with disease duration 
equal to or less than 5 years and in 18.9 % of patients 
with disease duration longer than 5 years, thus indi-
cating that the risk of allergy to glucocorticosteroids 
increases with the duration of the disease. 
In the present study, the corticosteroids included 
in the European Baseline Series, i.e. tixocortol-21-
pivalate and 0.01% budesonide, a diagnostic allergen 











Duration of CE (years)
<5 (n=73) >5 (n=53)
No. % No. % No. % No. % No. % No. % No. %
A 3 3.7 2 4.3 5 4.0 1 3.0 4 4.3 1 1.4 4 7.5
B 12 15.0 6 13.0 18 14.3 3 9.1 15 16.1 7 9.6 11 20.1
C 7 8.7 3 6.5 10 7.9 1 3.0 9 9.7 5 6.8 5 9.4
D1 8 10.0 6 13.0 14 11.1 2 6.1 12 12.9 7 9.6 7 13.2
D2 8 10.0 5 10.9 13 10.3 3 9.1 10 10.7 7 9.6 6 11.3
*CE: contact eczema
Table 5. Prevalence of allergy to the group of steroids according to topical steroid used
Number of patients used 
steroids from group:
Positive reaction to steroids group
A B C D1 D2
No. % No. % No. % No. % No. %
A (n=74) 5 6.8 15 20.3 9 12.2 12 16.2 12 16.2
B (n=30) 1 3.3 6 20.0 4 13.3 4 13.3 5 16.7
C (n=12) 0 0.0 3 25.0 2 16.7 3 25.0 2 16.7
D1 (n=89) 4 4.5 18 20.2 10 11.2 14 15.7 13 14.6
D2 (n=40) 2 5.0 8 20.0 5 12.5 7 17.5 6 15.0
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for the B and D corticosteroid groups (22), identified 
86.4% cases of steroid allergy. Tixocortol pivalate is 
a group A steroid and regarded as the best marker 
of allergy to hydrocortisone (22). Hypersensitivity to 
one steroid was observed in 36.4% of patients, and 
more than one in the remaining 63.7%. The most fre-
quently obtained cross-reactions were between cor-
ticosteroids of groups B and D. As budesonide gives 
very frequent cross-reactions, it is regarded as one of 
the best markers of contact allergy to steroids; in this 
study, it identified 81.2% of patients with hypersensi-
tivity to corticosteroids. 
The concentration which should be used for cor-
ticosteroid allergen patch tests has not been deter-
mined. Some reports suggest that a high corticoste-
roid concentration increases allergen penetration, 
thus enabling effective demonstration of hypersen-
sitivity despite its strong anti-inflammatory effect, 
whereas others note that lower concentrations allow 
a hypersensitivity reaction to be obtained more quick-
ly (23). The results of the present study indicate that 
in 72.2% of cases both 0.1% and 0.01% budesonide 
gave a positive result, compared with 16.7% of cases 
with only 0.01% budesonide and 11.1% of cases with 
0.1% budesonide, suggesting that the steroid aller-
gen is more sensitive at a lower concentration.
In addition, 72.7% of patients with hypersensi-
tivity to corticosteroids were also sensitized to non-
steroidal haptens included in the European Baseline 
Series. These results confirm that polyvalent contact 
allergy to non-steroidal allergens is a risk factor for 
hypersensitivity to steroids. Reitamo reports that pa-
tients suffering from chronic dermatoses, and those 
who experience two or more positive tests with non-
steroidal haptens, are at an increased risk of allergy to 
corticosteroids (24). Increased incidence of allergy to 
steroids also occurs in patients with chronic eczema, 
atopic dermatitis, and leg ulcers (25). Contact allergy 
to glucocorticosteroids may affect 12.8% of patients 
with atopic dermatitis, 20% of patients with chronic 
eczema, and 40% of patients with chronic leg ulcers 
(25,26). In the present study, changes on the lower 
limbs occurred in 40.9% patients with corticosteroid 
allergy. 
CONCLUSION
There is no doubt contact allergy to corticoste-
roids represents a significant therapeutic problem in 
the treatment of chronic inflammatory dermatoses. 
Hypersensitivity to a topical corticosteroid should be 
suspected when dermatitis fails to respond to topi-
cal corticosteroid therapy or when it worsens during 
treatment. Factors that increase the risk of contact al-
lergy to corticosteroids include the chronicity of the 
disease and coexistence of polyvalent contact allergy 
to non-steroidal haptens. In the case of polyvalent 
allergy to corticosteroids of different groups, topical 
steroid should be chosen from the group for which 
there is no hypersensitivity. 
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